GLP-1 approval and obesity-drug pipeline tracker
A concise tracker for major oral, injectable, dual-, and triple-agonist obesity medicines. Status checked August 24, 2026; investigational products are not FDA approved unless explicitly stated.
| Medicine | US status | Route | Latest milestone | Source |
|---|---|---|---|---|
| Foundayo (orforglipron) | FDA approved | Once-daily oral tablet | Approved April 1, 2026 for chronic weight management | Primary source |
| CagriSema | NDA under FDA review | Once-weekly injection | Novo Nordisk submitted the weight-management NDA December 18, 2025 | Primary source |
| Retatrutide | Investigational; phase 3 program complete | Once-weekly injection | Lilly reported five positive phase 3 studies and plans an FDA submission in Q1 2027 | Primary source |
What the statuses mean
“Phase 3” means a product is being tested in late-stage trials; it does not mean the FDA has found it safe and effective. “Submitted” means an application is under regulatory review. Only “FDA approved” means the agency has approved a specific labeled use.
Related PeptideGrids comparisons
Compare orforglipron vs semaglutide, semaglutide vs tirzepatide vs retatrutide, or browse all GLP-1 evidence grades.
This page reports regulatory and development milestones; it does not predict approval or provide treatment advice.